Johnson & Johnson’s trials show 66% efficacy in global trial, but 85% efficacy against severe Covid-19 disease

Johnson & Johnson’s Covid-19 single-shot vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% efficacy against severe disease, the company announced Friday.

Must Read

FAA met to discuss more frequent engine inspections days before Denver...

0
Only days before a dramatic engine failure on a United Airlines flight, federal regulators had met about requiring more frequent inspections of the same...